|
Volumn 50, Issue 56, 2014, Pages 7427-7430
|
The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
CISPLATIN;
DRUG COMBINATION;
NONSTEROID ANTIINFLAMMATORY AGENT;
ASCORBIC ACID;
ASPLATIN;
DIMETHYL SULFOXIDE;
GLUTATHIONE;
LIPOCORTIN 5;
OXOPLATIN;
PROPIDIUM IODIDE;
SATRAPLATIN;
UNCLASSIFIED DRUG;
ANIMAL;
CHEMISTRY;
DRUG COMBINATION;
DRUG EFFECTS;
DRUG POTENTIATION;
DRUG SCREENING;
HEPG2 CELL LINE;
HUMAN;
MCF 7 CELL LINE;
MOUSE;
NONOBESE DIABETIC MOUSE;
PROCEDURES;
SCID MOUSE;
TUMOR CELL LINE;
TUMOR VOLUME;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
CANCER CELL LINE;
CANCER INHIBITION;
CANCER RESISTANCE;
CANCER SIZE;
CELL VIABILITY;
CYTOTOXICITY;
DRUG DNA BINDING;
DRUG UPTAKE;
ELECTROSPRAY MASS SPECTROMETRY;
FLOW CYTOMETRY;
GENE TARGETING;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN CELL;
MTT ASSAY;
NONHUMAN;
PROTON NUCLEAR MAGNETIC RESONANCE;
REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
STOICHIOMETRY;
ANIMALS;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
ANTINEOPLASTIC AGENTS;
ASPIRIN;
CELL LINE, TUMOR;
CISPLATIN;
DRUG COMBINATIONS;
DRUG SYNERGISM;
HEP G2 CELLS;
HUMANS;
MCF-7 CELLS;
MICE;
MICE, INBRED NOD;
MICE, SCID;
TUMOR BURDEN;
XENOGRAFT MODEL ANTITUMOR ASSAYS;
|
EID: 84902674904
PISSN: 13597345
EISSN: 1364548X
Source Type: Journal
DOI: 10.1039/c4cc00419a Document Type: Article |
Times cited : (160)
|
References (24)
|